The adjuvant effects of CpG motif and activated large number of activated-T lymphocytes on immunoresponses.

我们研究了CpG基序质粒与HIV-DNA疫苗共同施用或将大量活化的T细胞转移到接种疫苗的同基因小鼠体内是否可以增强特异性免疫反应。将cpg富集质粒与DNA疫苗联合施用于Balb/c小鼠可显著提高hiv特异性细胞介导和体液免疫。含有最多拷贝数（20 CpG）的质粒是最有效的免疫增强剂。将正常BALB/c脾细胞用IL-2培养于抗小鼠CD3抗体包被烧瓶中。淋巴细胞数量增加约10倍。流式细胞术表型分析显示，该细胞群中CD8+/Thy1.2+细胞占60%，CD4+/Thy1.2 +细胞占18.5%，CD19 +细胞占8.9%。这些活化的细胞通过i.p.途径转移到接种了HIV-DNA疫苗的小鼠体内。结果表明，DNA疫苗接种2天后，转移激活的T细胞增加了特异性细胞和体液免疫。CpG基序质粒和转移激活的T淋巴细胞均表现出较强的佐剂活性。这些辅助方法不仅可以在人群中诱导hiv介导的免疫反应，还可以诱导其他传染病介导的免疫反应。这些给药方法简单、无副作用且安全，因此可能具有临床效益。

We examined whether the co-administering the CpG motifs plasmid with HIV-DNA vaccine or the transfer of a large number of activated T cells to syngenic mice immunized with vaccine can augment the specific immune responses. Co-administering the CpG-enriched plasmids with a DNA vaccine to Balb/c mice significantly increased HIV-specific cell mediated and humoral immunity. Plasmids containg a most of number of copies (20 CpG) were the most effective immune enhancers. Spleen cells from normal BALB/c were cultured with IL-2 in the anti-mouse CD3 Ab-coated flask. The number of lymphocytes increased about 10-fold.Phenotyping analysis by flow cytometry showed, this cell population contained about 60% of CD8+/Thy1.2+, 18.5% of CD4+/Thy1.2 + and 8.9% of CD19 + cells. These activated cells were transferred via the I. p. route to mice immunized with HIV-DNA vaccine. Results indicated that transfer activated T cells 2 days after DNA vaccination increased specific cellular and humoral immunity. Both co-administering the CpG motif plasmid and the transfer activated T lymphocytes showed stronger adjuvant activity. These adjuvant methods may induce not only HIV-mediated immune responses but also other infectious diseases-mediated immune responses in the human population as well. These administrations are likely to be of clinical benefit because their simplicity, lack of side effects and safety.